Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Health economics: Life in the balance

How do researchers and policy-makers decide on the value of health? Daniel Cressey looks at Britain's National Institute for Health and Clinical Excellence.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Thompson Coon, J. et al. Bevacizumab, Sorafenib tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation (Peninsula Technology Assessment Group, 2008).

  2. Escudier, B. et al. Lancet 370, 2103-2111 (2007).

    Article  Google Scholar 

  3. National Institute for Health and Clinical Excellence Final Appraisal Determination: Sunitinib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (NIH, 2009).

Download references


Additional information

See Editorial, see page 315 .

Related links

Related links

Related external links



Centre for Health Economics at York

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cressey, D. Health economics: Life in the balance. Nature 461, 336–339 (2009).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing